Title:
細胞内浸透能を有する抗ＳＴＡＴ３二重特異性抗体およびこれを含む薬学的組成物
Document Type and Number:
Japanese Patent JP7130274
Kind Code:
B2
Abstract:
The present invention relates to an anti-STAT3 specific antibody and a pharmaceutical composition comprising the same, and more specifically relates to an anti-STAT3 specific antibody which includes a site that specifically binds to STAT3, and further include a STAT3 site plus a DNA binding site that confer cell penetration ability, and a pharmaceutical composition comprising it as an active ingredient. The STAT3 specific antibody according to the present invention, and particularly the STAT3/DNA dual specific antibody having a dual specific characteristic, contains a DNA binding site that can penetrate cells and specifically bind to DNA in the nucleus, and thus can overcome the limitations of conventional antibody therapeutics that can target only extracellular proteins. It has been also confirmed that the antibody can inhibit transcription factor activity of STAT3 by specifically binding to phosphorylated activated form of STAT3. So, the antibody could be used for the development of a therapeutic agent without side effects for various diseases caused by activation of STAT3, for example, a therapeutic agent for carcinoma, a drug capable of inhibiting cancer metastasis progressed by activation of STAT3, and a therapeutic agent without side effects for inflammatory diseases including rheumatoid arthritis and psoriatic dermatitis also caused by activation of STAT3.
More Like This:
Inventors:
Ham Seong-ho
Hong Jin Tae
Hong Jin Tae
Application Number:
JP2020555000A
Publication Date:
September 05, 2022
Filing Date:
December 21, 2018
Export Citation:
Assignee:
LofiBio Inc.
International Classes:
C12N15/13; A61K39/395; A61P19/02; A61P29/00; A61P35/00; A61P35/04; C07K16/18; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/63; C12P21/08; G01N33/53
Domestic Patent References:
| JP2012508762A | ||||
| JP2000507225A |
Foreign References:
| WO2017189588A1 | ||||
| WO2016115500A1 |
Other References:
Nancy L. Goicochea, et al.,Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy.,Protein Engineering, Design& Selection,2017年12月06日,Volume 30, Issue 12,p.785-793
Attorney, Agent or Firm:
Tomoharu Ashikita
Atsushi Ido
Atsushi Ido